+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Caspase 7 - Drugs In Development, 2021

  • ID: 5359611
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 56 pages
  • Global Markets Direct

FEATURED COMPANIES

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Caspase-7 (CASP7) is a human protein encoded by the CASP7 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves and activates sterol regulatory element binding proteins.

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology, Dermatology, Genito Urinary System and Sex Hormones, Immunology, Metabolic Disorders and Ophthalmology which include indications Age Related Macular Degeneration, Atopic Dermatitis (Atopic Eczema), Coronavirus Disease 2019 (COVID-19), Diabetic Retinopathy, Glomerulonephritis, Psoriasis, Solid Tumor and Zika Virus Infections.

The latest report Caspase 7 - Drugs In Development, 2021, outlays comprehensive information on the Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)
  • The report reviews Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

Introduction
  • Report Coverage
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Overview

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Companies Involved in Therapeutics Development
  • Clayton Biotechnologies Inc
  • Derm-Biome Pharmaceuticals Inc
  • Histogen Inc
  • Takeda Pharmaceutical Co Ltd
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Drug Profiles

BaxB-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
DB-207 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
emricasan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
emricasan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Dormant Products

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Discontinued Products

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Product Development Milestones

Featured News & Press Releases
  • May 19, 2021: Histogen and Amerimmune report publication on Emricasan in COVID-19
  • Mar 16, 2021: Histogen and Amerimmune announce first patient dosed in phase 1 study of Emricasan in symptomatic COVID-19 patients
  • Oct 06, 2020: Derm-Biome Pharmaceuticals reports positive results from a preclinical study in psoriasis
  • Jun 24, 2019: Conatus announces results from ENCORE-LF and ENCORE-PH phase 2b clinical trials in NASH Cirrhosis
  • Jun 24, 2019: Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis
  • Apr 30, 2019: Conatus Pharmaceuticals announces publication demonstrating that Emricasan Ameliorates Portal Hypertension, improves liver structure and function in a preclinical model of advanced cirrhosis
  • Apr 15, 2019: Conatus late-breaker oral presentation at EASL meeting details results of ENCORE-PH phase 2b clinical trial in patients with NASH cirrhosis and severe portal hypertension
  • Mar 21, 2019: Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis
  • Mar 13, 2019: Conatus Late-breaker oral presentation at EASL meeting to detail results of ENCORE-PH Phase 2b clinical trial in patients with NASH Cirrhosis and Severe Portal Hypertension
  • Feb 12, 2019: Conatus announces completion of enrollment in ENCORE-LF phase 2b clinical trial of Emricasan in patients with decompensated NASH cirrhosis
  • Jan 28, 2019: Conatus Pharmaceuticals announces publications expanding on previously reported results from completed phase 2 NAFLD-NASH, portal hypertension and liver cirrhosis clinical trials
  • Dec 05, 2018: Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
  • Oct 26, 2018: Derm-Biome Pharmaceuticals commences testing its proprietary compounds on skin microbiome targets.
  • Sep 20, 2018: Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
  • Jul 02, 2018: Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Clayton Biotechnologies Inc, 2021
  • Pipeline by Derm-Biome Pharmaceuticals Inc, 2021
  • Pipeline by Histogen Inc, 2021
  • Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Clayton Biotechnologies Inc
  • Derm-Biome Pharmaceuticals Inc
  • Histogen Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll